Agnes Kant

Agnes Kant

Auto-generated profile, based on publicly available information

Agnes Kant

Netherlands Pharmacovigilance Centre Lareb 's‐Hertogenbosch The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Drug Safety
Verified
Journal Article
Closed access
PDF file
AKAgnes Kant
Agnes Kant
JJJurriaan Jansen
Jurriaan Jansen
LBLeontine van Balveren
Leontine van Balveren
FHFlorence van Hunsel
Florence van Hunsel

6 August 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
AKAgnes Kant
Agnes Kant
FHFlorence van Hunsel
Florence van Hunsel
EPEugene van Puijenbroek
Eugene van Puijenbroek


25 June 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
JDJanneke W. Duijster
Janneke W. Duijster
MSMark E. Schoep
Mark E. Schoep
TNTheodoor E. Nieboer
Theodoor E. Nieboer
RJRana Jajou
Rana Jajou
AKAgnes Kant
Agnes Kant
FHFlorence van Hunsel
Florence van Hunsel

9 November 2022 in Drug Safety
Verified
Journal Article
Open access
PDF file
IOIngrid Oosterhuis
Ingrid Oosterhuis
JSJoep Scholl
Joep Scholl
EPEugene P. Van Puijenbroek
Eugene P. Van Puijenbroek
AKAgnes Kant
Agnes Kant
FHFlorence van Hunsel
Florence van Hunsel
Introduction Due to the COVID-19 vaccination campaign, national pharmacovigilance (PV) centres had to deal with high volumes of Individual Case Safety Reports (ICSRs) that needed to be processed and assessed in a short time span. This necessitated the development of a dedicated system to enable near real-time vaccine safety monitoring at the Dutch PV Centre Lareb. Objectives To describe infrastructure, processes and Adverse Events Following Immunisation (AEFIs) reported for vaccine safety monitoring of COVID-19 vaccines during a large-scale vaccination campaign in the Netherlands. Methods A COVID-19 tailored vaccine web-based reporting form collected information on the vaccine administered, AEFIs and other (medical) information. A fully automated process for ICSRs enabled the handling of the majority of common and known reported AEFIs. All other ICSRs were triaged daily and processed separately. There were daily signal detection meetings and weekly reports for batch analysis. Results In 2021, Lareb received 184,411 ICSRs, a reporting rate of 0.67% for vaccines given in the Netherlands. 887,954 AEFIs were reported, mostly well-known, nonserious AEFIs; 2.4% were serious and 0.3% were fatal. 33.1% of all ICSRs were processed fully automatically. Based on the daily triage, 4.2% were flagged as ‘high priority’; 62.7% as ‘low-priority’. Twenty-seven signals and news stories about the COVID-19 vaccines were disseminated. Conclusions Due to automatic processing of well-known AEFIs, daily triage and signal detection meetings, 99.9% of the ICSRs were processed within the compliance timeframe to Eudravigilance, and signal detection was performed during a large-scale vaccination campaign. These experiences may serve as a blueprint for future mass vaccination programs.

16 May 2024 in Journal of Medical Systems
Verified
Journal Article
Open access
PDF file
HKH. Abedian Kalkhoran
H. Abedian Kalkhoran
JZjuliette zwaveling
juliette zwaveling
FHFlorence van Hunsel
Florence van Hunsel
AKA. Kant
A. Kant
Reports from spontaneous reporting systems (SRS) are hypothesis generating. Additional evidence such as more reports is required to determine whether the generated drug-event associations are in fact safety signals. However, underreporting of adverse drug reactions (ADRs) delays signal detection. Through the use of natural language processing, different sources of real-world data can be used to proactively collect additional evidence for potential safety signals. This study aims to explore the feasibility of using Electronic Health Records (EHRs) to identify additional cases based on initial indications from spontaneous ADR reports, with the goal of strengthening the evidence base for potential safety signals. For two confirmed and two potential signals generated by the SRS of the Netherlands Pharmacovigilance Centre Lareb, targeted searches in the EHR of the Leiden University Medical Centre were performed using a text-mining based tool, CTcue. The search for additional cases was done by constructing and running queries in the structured and free-text fields of the EHRs. We identified at least five additional cases for the confirmed signals and one additional case for each potential safety signal. The majority of the identified cases for the confirmed signals were documented in the EHRs before signal detection by the Dutch Medicines Evaluation Board. The identified cases for the potential signals were reported to Lareb as further evidence for signal detection. Our findings highlight the feasibility of performing targeted searches in the EHR based on an underlying hypothesis to provide further evidence for signal generation.